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Objective: To assess the effectiveness of infliximab (Remicade) in the treatment of
patients with sarcoidosis who either do not respond to corticosteroids and other
conventional drugs or develop unacceptable side effects to these drugs.
Design: A clinical, non-randomized, off-label study.
Setting: Sarcoidosis clinic at a university teaching hospital.
Patients: Twelve biopsy-proven sarcoidosis patients, nine women and three men
ranging from 45 to 70 years of age with chronic multisystem sarcoidosis refractory to
corticosteroids or alternative treatment.
Intervention: Infliximab was infused at a dedicated ambulatory infusion center. The
initial dose was 3mg/kg body weight and subsequent doses were given at weeks 2, 4,
6, 10, and 14. All patients received at least six infusions.
Results: All 12 patients improved significantly. One patient had a mild allergic drug
reaction that responded to antihistamine. One patient, after 3 months of stopping
infliximab treatment, died of a ruptured blood vessel in the abdomen. At autopsy a
plasma cell dyscrasia was found.
Conclusion: Infliximab is safe and effective in treating those patients with
multisystem sarcoidosis who are either refractory or develop side effects to a
standard regimen of corticosteroids and immunosuppressive agents.
& 2006 Published by Elsevier Ltd.Published by Elsevier Ltd.
Om Sharma, MD, FRCP,
dical Center, Division of
tate Street, RM 11900 Los
(O.P. Sharma).Introduction
There is no cure for sarcoidosis. Corticosteroids are
universally used for suppressing the progressive and
harmful granulomatous inflammation associated
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S. Saleh et al.2054with the disease. Unfortunately, many develop
intolerable side effects that become more of a
problem than the illness itself. In such a situation, a
number of alternative drugs, including immunosup-
pressive agents (azathioprine, cyclophosphamide,
methotrexate), immune modulators (pentoxyphyl-
line, thalidomide), non-cytotoxic anti-inflamma-
tory agents (chloroquine, hydroxychloroquine),
and radiation have been used. These drugs are
not consistently effective and many have serious
side effects. Thus, the search for an ideal drug for
the treatment of sarcoidosis continues. Recent
studies have shown that tumor necrosis factor-a
(TNF-a) plays an important role in perpetuating the
granulomatous inflammation. Infliximab, a tumor
necrosis factor antagonist, blocks the effect of
tumor necrosis factor and exerts a beneficial effect
by controlling sarcoidosis. We present the results of
12 patients with multisystem sarcoidosis who were
treated with infliximab.Patients and methods
Between 2001 and 2003, 12 patients with sarcoi-
dosis at the Ambulatory Health Care Center of the
Keck School of Medicine received infliximab. These
patients had clinical as well as histological evi-
dence of sarcoidosis. They were either refractory
to treatment with corticosteroids and/or alterna-
tive drugs or had developed severe side effects,
including depression, psychosis, suicidal tendency,
brittle hyperglycemia, unmanageable obesity, and
osteoporosis. All patients had a negative tuberculin
test. They were also screened for latent tubercu-
losis by a detailed past medical, family, and social
history, including travel to countries where tuber-
culosis is endemic. All patients were examined and
evaluated by one physician. Infliximab was admi-
nistered in an outpatient infusion clinic. The initial
dose was 3mg/kg body weight and subsequent
doses were given at weeks 2, 4, 6, 10, and 14; all
patients received at least six infusions. Additional
doses were given at 8-week-intervals for those who
did not respond or for those who had an initial
response and then a relapse. In most of the
patients, corticosteroids were reduced or discon-
tinued. Methotrexate was continued during inflix-
imab therapy.Figure 1 Cutaneous lesions on the chest: (a) before and
after (b); on the back before (c) and after (d); on the legs
before (e) and after (f) six infusions of infliximab, 3mg/
kg body weight (#1 in Table 1).Results
The clinical, radiological, and histological, features
of 12 patients are summarized in Table 1. Allpatients had chronic sarcoidosis of at least 3 years
duration. The following representative patients are
described in detail.
Case 1 (Case #1 in Table 1)
In 1986, this 29-year-old Caucasian woman devel-
oped skin lesions and hilar lymphadenopathy. A
hilar lymph node biopsy confirmed the diagnosis of
sarcoidosis. First, her skin lesions were treated
with topical steroids. Later when the lesions
worsened, she was given oral prednisone and
hydroxychloroquine. Prednisone was discontinued
because of weight gain, psychological problems,
and insomnia. Over the next 10 years, the patient
was treated with methotrexate, triamcinolone
injections, thalidomide, and cyclophosphamide. In
2002, her skin lesions became more prominent and
disfiguring. From June to August, the patient
received three infusions of infliximab at 3mg/kg
body weight and methotrexate 10mg once per
week. She tolerated the first two injections well;
however, after the third injection, she developed
itching and mild urticaria, both of which were
alleviated by an antihistamine. After the fourth
injection, her skin lesions had subsided by 85%;
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S. Saleh et al.2056after the sixth injection, the skin lesions had almost
completely disappeared (Fig. 1a–f). Hilar adeno-
pathy and the lung function remained unchanged.Case 2 (Case #2 in Table 1)
In 1999, this 58-year-old Caucasian woman devel-
oped fever, weight loss, erythema nodosum, and
sub-cutaneous nodules (Derrier–Roussey syndrome).
A biopsy of one of the nodules showed non-caseating
granulomas. No treatment was given. In March 2001,
the patient was found to have involvement of the
liver and splenomegaly. A splenectomy was per-
formed to exclude lymphoma. However, perihilar
lymph nodes and a liver biopsy, showed non-case-
ating granulomas. In September 2002, the patient
developed dizziness, memory loss, ataxia, and
tingling in her hands and feet. A CT of the brain
showed changes consistent with the diagnosis of
neurosarcoidosis. Prednisone 60mg per day and
methotrexate 20mg once per week were started.
In January 2003, her skin lesions returned and she
developed hypercalcemia. Methotrexate was dis-
continued and azathioprine 100mg/day added. With
the onset of depression, the prednisone dose was
reduced. Infliximab 3mg/kg of body weight was
started. Between March and October 2003, she
received six infusions. Skin lesions subsided, serum
calcium and alkaline-phosphatase levels became
normal, neurological symptoms improved, serum
angiotensin converting enzyme level came down
from 185 to 167 IU, and CT of the brain improved
(Fig. 2a,b). She responded to infliximab therapy and
remained well for about 3 months before developing
a fatal abdominal hemorrhage due to a superior
mesenteric artery dissection. Autopsy revealed a
plasma cell dyscrasia.Figure 2 Computerized tomography of brain (a) before
and (b) after infliximab therapy (#2 in Table 1).Case 3 (Case #3 in Table 1)
In 1965, this 18-year-old Caucasian man was found
to have bilateral hilar adenopathy on a chest X-ray
film. A cervical lymph node biopsy showed non-
caseating granulomas. No treatment was given. In
1970, he developed lupus pernio. At first, the rash
was treated with topical corticosteroids. The
patient declined to take prednisone. A trial of
methotrexate failed to halt the progression of the
rash. Hydroxychloroquine, azathioprine, doxycy-
cline, and thalidomide were tried. None of the
drugs succeeded; either the patient developed side
effects or the drug was ineffective. In August 2001,
infliximab 3mg/kg body weight was started. His
lupus pernio cleared after eight infusions
(Fig. 3a,b). The skin lesions recurred after 3 months
and infliximab was resumed. He received a total of
13 infusions and remains off therapy. The patient
developed high ANA titers that fluctuated sponta-
neously. The ANA pattern remained homogenous.
There were no changes in liver or kidney functions.
Sedimentation rate, CRP, and rheumatoid factor
remained normal.Case 4 (Case #4 in Table 1)
In 2001, this 61-year-old Caucasian woman devel-
oped a dry cough. A chest X-ray film showed
bilateral hilar adenopathy. Mediastinal node biopsy
revealed non-caseating granulomas. Since she had
no symptoms, no treatment was given. In 2002, the
patient became ataxic. An MRI revealed intrame-
dullary lesions in the cervical and thoracic spinal
cord. The clinical course was consistent with
neurosarcoidosis. She was started on methotrexate
20mg once a week. Because of her obesity,
glaucoma, depression, and a family history of
diabetes mellitus, prednisone was not given.
Despite a 6-month course of treatment with
methotrexate, her neurological symptoms wor-
sened. In addition to ataxia she developed muscle
weakness. In November 2003, she was started onFigure 3 Lupus pernio: before and after infliximab
treatment (#3 in Table 1).
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Figure 5 Diffuse bone lesions (a) before and after (b)
infliximab (#5 in Table 1).
Figure 4 MRI lesions before (a) and after infliximab
therapy (b). Arrow points to representative lesions in (a)
(#4 in Table 1).
Infliximab in treating patients with sarcoidosis 2057Infliximab 3mg/kg body weight. After six infusions
her neurological symptoms improved. The MRI in
Fig. 4 shows the radiographical evidence of
improvement.Case 5 (Case #5 in Table 1)
In 1995, this 42-year-old Caucasian woman devel-
oped shortness of breath. In 1996, a skin biopsy
established the diagnosis of sarcoidosis. In 1997,
her dyspnea worsened and a chest X-ray film was
consistent with stage III pulmonary involvement.
She was treated with prednisone for approximately
2 years. In 2000, her symptoms progressed to
include fatigue, bone pains, and low-grade fevers.
Prednisone was reduced and methotrexate 20mg
once per week was added. A bone scan in January
2001 and a whole body gallium scan showed lesions
in the femoral shaft, the hip bones and the skull. A
2-year trial of methotrexate failed to improve her
symptoms. In February 2002, she was started on
infliximab. After the third infusion, her bone pain
subsided and the systemic symptoms of low-grade
fever and fatigue subsided. A bone scan showed
marked improvement (Fig. 5a,b). After eigtht
infusions, infliximab was discontinued but metho-
trexate was continued. In March 2003, 3 months
after infliximab was discontinued, her symptoms
returned. Her bone marrow became hypermeta-
bolic and areas of inflammation appeared in the
left sacral and right orbital areas. She was given
another course of infliximab with improvement.Discussion
Infliximab is a chimeric (mouse/human) IgG-1 anti-
TNF-a monoclonal antibody that binds to soluble
transmembrane TNF-a with high affinity and forms
a stable complex that blocks the union of this
cytokine with its receptor. Inhibition of TNF-a is
achieved in vitro with infliximab concentrations of
0.2–10 mg/ml.1 Infusions of 3 or 10mg/kg Infliximab
at weeks 0, 2 and 6 produce predictable, effective
serum drug concentrations and are superior to
placebo.2 The frequent development of anti-inflix-
imab antibodies requires the use of methotrexate
in combination, rather than monotherapy with
infliximab.3,4 Infliximab also kills the cells that
express TNF-a through antibody-dependent and
complement-dependent cytotoxicity.4 Clinical stu-
dies in rheumatoid arthritis have established a
standard regimen.3,5,6 If patients do not respond to
the standard dose or have an initial response
followed by a relapse, then they may have a better
response if the interval between infusions is
decreased or the dose is increased.2,7 TNF-a plays
a role in the pathogenesis of many chronic
inflammatory diseases. TNF blocking therapy with
infliximab or etanercept is effective in many
diseases including rheumatoid arthritis, Crohn’s
disease, ankylosing spondylitis, and psoriatic ar-
thritis.8–10 TNF-a also plays an important role in
modulating the granulomatous inflammation of
sarcoidosis.11,12 High levels of tumor necrosis factor
are found at the site of inflammation.13 Corticos-
teroids, methotrexate, and azathioprine suppress
TNF-a production by alveolar macrophages in
ARTICLE IN PRESS
S. Saleh et al.2058sarcoidosis.14 In sarcoidosis, there are no guidelines
regarding the indications, dose, and duration of
therapy, and assessing response of the disease to
infliximab. A limited number of sarcoidosis patients
have been treated with infliximab.15–22 Our study
was not a prospective, controlled, double-blind
study; infliximab was not compared with predni-
sone or any of the other drugs used in controlling
sarcoidosis. Infliximab was used because of the
presence of one or more of the following:1 Patients with sarcoidosis who failed to respond
to corticosteroids.2 Patients who responded favorably to corticos-
teroids but did not wish to continue because of
severe side effects.3 Patients who developed either side effects to or
failed treatment with chloroquine, hydroxy-
chloroquine, azathioprine, methotrexate, or
cyclophosphamide.4 Patients who could tolerate only methotrexate
in small doses, but whose severity of the disease
required adding another drug that the patient
could not tolerate. Although infliximab was
effective in suppressing the granulomatous
inflammation, the illness recurred in four
patients, 2–6 months after the initial course of
six infusions had ended.5 Patient who required a second course of inflix-
imab infusion to control bone pains.
Infliximab was effective not only in controlling
the skin lesions of sarcoidosis, but also in favorably
influencing bone, pulmonary, neural, and lymph
node involvement due to sarcoidosis. In Patient #9,
hypercalcemia responded to infliximab, although
the drug was given for enlarged lymph nodes. There
were only a few side effects attributable to
infliximab. No patient developed side effects
warranting discontinuation or interruption of treat-
ment. Increased autoantibody production has been
reported with the use of infliximab.3,4,6 Repeated
treatment with the drug may lead to the develop-
ment of human antichimeric antibodies (HACA). We
did not measure such antibodies. The development
of HACA can be associated with hypersensitivity
reactions after the drug infusion.23 In patient #3
anti-nuclear antibody levels increased but these
elevations were transient and were not associated
with other hematologic or immunologic changes.
None of the patients experienced significant aller-
gic or anaphylactic reaction. None developed any
serious pulmonary or extrapulmonary infections,
although an increased risk of opportunistic infec-
tions (including tuberculosis and fungi) has been
reported in patients treated with infliximab.6,24–26An increased incidence of lymphoma and malig-
nancy has been reported in patients with rheuma-
toid arthritis and sarcoidosis who received
infliximab, but it is unclear if the risk was related
to the primary illness or previous immunosuppres-
sive treatment or infliximab.27–29 One of our
patients (#2) developed myeloma after termination
of infliximab therapy. We believe it was unrelated
to both sarcoidosis and infliximab.
In conclusion, infliximab is effective in control-
ling different manifestations of sarcoidosis that are
resistant to conventional therapy. It is particularly
beneficial in progressive, inexorable cutaneous
sarcoidosis that is poorly responsive to, or is non-
responsive to corticosteroids and immunosuppres-
sive agents. It appears that in order for the drug to
be active it would need to be given intermittently
over a long period of time. Often, a recurrence of
symptoms may be seen upon discontinuation of the
drug, which may necessitate another course of
treatment. Once the aggressive inflammation is
brought under control, the disease can then be
kept subdued with methotrexate, hydroxychloro-
quine, or azathioprine. It is an expensive drug.
Furthermore, long-term impact of the drug in
patients with sarcoidosis who have a complex
immunopathogenesis is not known. The drug is
likely to find its niche in controlling overwhelming
granulomatous inflammation affecting the vital
organs like the eyes and the central nervous
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